Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
S Damodaran, F Zhao, DA Deming… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Activating mutations in PIK3CA are observed across multiple tumor types. The
NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted …
NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted …
[HTML][HTML] Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
S Damodaran, F Zhao, DA Deming… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Activating mutations in PIK3CA are observed across multiple tumor types. The
NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted …
NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted …
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
S Damodaran, F Zhao… - … official journal of …, 2022 - utsouthwestern.elsevierpure.com
PURPOSE: Activating mutations in PIK3CA are observed across multiple tumor types. The
NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted …
NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted …
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
S Damodaran, F Zhao, DA Deming… - Journal of Clinical …, 2022 - europepmc.org
Purpose Activating mutations in PIK3CA are observed across multiple tumor types. The NCI-
MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted therapies …
MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted therapies …
Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
S Damodaran, F Zhao… - Journal of …, 2022 - mdanderson.elsevierpure.com
PURPOSEActivating mutations in PIK3CA are observed across multiple tumor types. The
NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted …
NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted …
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
S Damodaran, F Zhao, DA Deming… - Journal of Clinical …, 2022 - ingentaconnect.com
PURPOSE Activating mutations in PIK3CA are observed across multiple tumor types. The
NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted …
NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted …
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
S Damodaran, F Zhao, DA Deming… - Journal of clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose Activating mutations in PIK3CA are observed across multiple tumor types. The NCI-
MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted therapies …
MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted therapies …